Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
87
resultados
Última actualización
11/06/2026 [07:13:00]
Resumen de: AU2026203814A1
The present disclosure relates generally to compositions, dosage forms, and methods for preventing and treating infections. The compositions include intact and substantially non- viable Gram-negative bacterial cells which have been treated to reduce lipopolysaccharide (LPS)-associated endotoxin activity, which surprisingly have increased activity to trigger immune cell production of cytokines. ay a y
Resumen de: MX2026005882A
Disclosed herein are methods and systems for rapid detection of microorganisms such as Listeria spp. in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene in the late gene region. The specificity of the bacteriophage, such as Listeria-specific bacteriophage, allows detection of a specific microorganism, such as Listeria spp. and an indicator signal may be amplified to optimize assay sensitivity.
Resumen de: US20260144857A1
Technologies for the prevention and/or treatment of Shigella infections.
Resumen de: WO2026108702A1
Disclosed in the present invention are a nanobody for detecting Escherichia coli O157:H7 and a preparation method therefor. The present invention aims to provide a nanobody for detecting Escherichia coli O157:H7 with high detection accuracy and a simple acquisition method. The amino acid sequence of the nanobody is set forth in SEQ ID NOs. 1-3. The present invention belongs to the technical field of biopharmaceuticals.
Resumen de: US20260146994A1
A system and method for detecting, enumerating, or extracting microorganisms in a sample is disclosed. Target microorganisms, such as Salmonella bacteria, may be of interest. Magnetic beads may be bound to the target microorganisms. After which, the bead-bound cells may be isolated. For example, a magnetic field may be applied in order to separate the target cells (with the magnetic beads attached thereto) and move then to a predetermined section of the well. Agar, or other immobilizing agent, may be added to the wells in order to immobilize the target cells. After which, the target cells are incubated and periodically analyzed to determine whether the target cells are growing, thereby indicating that the microorganisms are contained within the well.
Resumen de: WO2025021695A1
The present invention relates to immunogenic compositions comprising outer membrane vesicles (OMVs) adsorbed to an aluminium hydroxide adjuvant, whereby the aluminium hydroxide adjuvant is quenched. The present invention also relates to the use of the immunogenic compositions for providing protection against diseases caused by Gram-negative bacteria. The present invention also relates to a method for reducing particle aggregation and/or average particle diameter in compositions comprising OMVs and an aluminium hydroxide adjuvant.
Resumen de: CN122081186A
本发明公开了一种三级淋巴结构生物模型的构建方法，可以快速高效诱导原位TLS的产生，不依赖于特定的组织器官，不需要细胞编辑、转基因小鼠等复杂昂贵的制备流程，在2～3周内产生稳定、成熟、存续时间长的TLS结构，具有周期短、成本低、操作简单、可重复、安全有效的特点。
Resumen de: CN118846069A
The invention relates to the field of medicine, in particular to a pharmaceutical composition and a preparation method and application thereof.The pharmaceutical composition comprises a first effective component, a second effective component and a pharmaceutically acceptable carrier or auxiliary material, the microbial agent comprises any one or more of staphylococcus aureus, bordetella pertussis, diphtheria toxoid, tetanus toxoid, typhoid bacillus or paratyphoid bacillus, and the second effective component comprises polyinosinic acid, polycytidylic acid and vitamin. The pharmaceutical composition belongs to artificial active immunotherapy aiming at tumors, can'stimulate 'the whole immune system, enables the therapy of activating the human immune system by bacteria to kill cancer cells to be quite stable and reliable, can remarkably save and prolong the life of cancer patients, has extremely high safety and extremely small toxic and side effects, and is suitable for clinical application. And the preparation cost is low.
Resumen de: CN122081185A
本发明属于生物医药技术领域，公开了一种用于肿瘤原位表达微管抑制蛋白的工程化细菌及其应用。通过将微管抑制蛋白基因构建至表达载体，最终转入细菌，形成工程菌。该工程菌能靶向定植于肿瘤微环境，表达微管抑制蛋白，有效抑制肿瘤细胞，显著抑制实体瘤生长，且安全性优良。
Resumen de: US20260140114A1
The disclosure provides methods, compositions, and kits for enhanced detection of microbes in samples and monitoring of antimicrobial activity in a subject.
Resumen de: US20260139012A1
A method for increasing the presentation of ETEC CS6 antigen on a cell surface, comprising the step of contacting cells expressing said antigen with an aqueous solution comprising 0.6-2.2 percent phenol by weight, such that the presentation of said antigen is increased by at least 100%. A method for the manufacture of a killed whole cell vaccine for immunization against CS6-expressing ETEC. Cells and vaccines obtainable by the above methods.
Resumen de: AU2026203336A1
Outer membrane vesicles from bacteria of the Burkholderia pseudomallei complex can be used as adjuvants in compositions and methods to potentiate the immune response to immunogens. ay a y
Resumen de: US20260137765A1
A method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.
Resumen de: US20260137738A1
The present invention relates to a novel bacteriophage OPT-SALO1 with specific killing ability for Salmonella enterica, an antibiotic composition comprising the bacteriophage, a composition for adding to a feed, a feed, a disinfectant or a cleaning agent, and a method for preventing or treating infectious diseases caused by Salmonella enterica comprising a step of administering the bacteriophage to a subject.
Resumen de: WO2026102349A1
Interleukin-23 receptor (IL23R) VHH antibodies are disclosed, as well as methods of making and using the same, e.g., for treatment of IL23-mediated diseases and disorders, including, e.g., gastrointestinal-related (Gl-related) diseases (e.g., inflammatory bowel disease (IBD) (e.g., ulcerative colitis (UC) or Crohn's disease (CD)), a colon cancer, a small intestine cancer, a gastric cancer, an irritable bowel syndrome, a gastrointestinal ulcer, a gut-associated infection (e.g., a Salmonella infection or a Clostridium difficile infection), celiac disease, or pathogenic inflammation).
Resumen de: WO2026098490A1
Disclosed in the present application is the use of Salmonella typhimurium-derived glutamate dehydrogenase and related biomaterials thereof in amino acid synthesis. Provided in the present application is the use of Salmonella typhimurium-derived glutamate dehydrogenase for improving the L-amino acid yield of a microorganism. In the present application, an optimized coding gene of the Salmonella typhimurium-derived glutamate dehydrogenase is further obtained by means of codon optimization, and the introduction of the optimized coding gene into a recipient microorganism can significantly improve the L-amino acid yield of the recipient microorganism.
Resumen de: US20260131039A1
This disclosure relates to a method for sanitizing a space. The method includes applying a composition containing triethylene glycol into a space containing a pathogen (e.g., a Staphylococcus, a Pseudomonas, a Listeria, Salmonella, Klebsiella, a mycobacterium, a mold, or a spore) in an amount effective to inactivate the pathogen.
Resumen de: US20260132409A1
The present disclosure provides fusion proteins comprises fusion proteins comprising the signal sequence of PduB or PduM and a heterologous protein, as well as constructs for expressing the fusion proteins, and methods of their use. The fusion proteins are designed to deliver the heterologous proteins to bacterial microcompartments and modify the 1,2-propanediol metabolic pathway.
Resumen de: US20260124255A1
0000 A genetically modified Salmonella cell (GMSC) engineered to display pattern-associated and danger-associated molecular patterns to recruit and enhance innate immunity and exhibit specific targeting to cells and regulated delayed lysis in vivo, the GMSC comprising a first heterologous nucleic acid that encodes a first gene product that causes the GMSC to be selectively localized to and/or internalized by a target cell in vivo and a second heterologous nucleic acid that encodes a second gene product that facilitates killing of the target cells following internalization.
Resumen de: US20260124215A1
The present invention relates to compositions and methods for treating or preventing infections, in particular infections by intracellular parasites such as Cryptosporidium spp. The present invention also relates to compositions and methods for treating or preventing viral or bacterial infections, in particular intestinal infections such as those caused by rotavirus and Salmonella spp. Infections. The methods comprise administration of, and the compositions comprise, a farnesyl-diphosphate farnesyltransferase 1 (FDFT1) inhibitor, such as lapaquistat.
Resumen de: WO2025003117A1
The present invention relates to a gelled reaction medium for detecting, identifying, and/or isolating at least one Shiga toxin-producing strain of E. coli, the reaction medium comprising: - at least one toxin inducer, - at least one agglutinating conjugate comprising at least one specific binding partner of STX1 and/or at least one specific binding partner of STX2, coupled to a nanoparticle; - a concentration gradient of a compound for inhibiting non-target bacteria. The present invention also relates to the associated method for detecting and/or isolating Shiga toxin-producing E. coli which is likely to be present in a sample comprising enterobacteria.
Resumen de: WO2025003119A1
The invention relates to a method for detecting and confirming at least one Shiga toxin-producing Escherichia Coli (STEC) which may be present in a sample comprising enterobacteria, comprising the following steps: - performing lysis of the sample, enabling lysis of the STECs in order to obtain a solution comprising the nucleic acids thereof; - bringing the solution of nucleic acids into contact with primers, making it possible to amplify at least the stx1 and/or stx2 gene or gene fragment; - if at least one of the stx1 and/or stx2 genes or gene fragments is amplified, part of the sample is deposited on an agar reaction medium comprising ■ at least one toxin inducer, ■ at least one agglutinating conjugate formed by at least one binding partner specific to the STX1 protein and/or at least one binding partner specific to the STX2 protein, which binding partner(s) is (are) coupled to a nanoparticle; - detecting and confirming the presence of at least one STEC by the appearance of a halo on the agar around the STEC.
Resumen de: MX2025013800A
Disclosed herein are methods and systems for rapid detection of microorganisms in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene in the late gene region. The specificity of the bacteriophage, such as Salmonella-specific bacteriophage, allows detection of a specific microorganism, such as Salmonella spp. and an indicator signal may be amplified to optimize assay sensitivity.
Resumen de: WO2026089256A1
The present invention relates to an antibacterial composition against pathogenic bacteria, the composition comprising streptococcus salivarius g7 and lactobacillus plantarum gspe05, and specifically, exhibits high antibacterial activity against one or more bacteria selected from the group consisting of Bacillus cereus, Listeria monocytogenes, Salmonella typhimurium, Streptococcus mutans, Porphyromonas gingivalis, and Moraxella catarrhalis, and thus can contribute to the improvement of intestinal diseases, oral diseases, and respiratory diseases caused by these pathogenic strains.
Nº publicación: WO2026087718A1 30/04/2026
Solicitante:
INST PASTEUR [FR]
CENTRE NATIONAL DE LA RECHERCHE SCIENT [FR]
INSTITUT PASTEUR
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Resumen de: WO2026087718A1
The present invention, in embodiments, relates to a multivalent vaccine comprising a combination of two or more different monovalent Shigella oligosaccharide protein conjugates and an adjuvant. One of the vaccine components can be a Shigella sonnei oligosaccharide- protein conjugate and the other three can be Shigella flexneri oligosaccharide-protein conjugates, specifically, S. flexneri 2a, S. flexneri 3a and S. flexneri 6, respectively. All conjugates feature sOS components acting as surrogates of the heterogeneous Shigella surface polysaccharide antigens characteristic of each one of the selected Shigella serotypes. The multivalent vaccine of the present invention is made for the prevention and/or treatment of disease caused by Shigella, in particular S. sonnei and S. flexneri.
BOPI
Sede Electrónica
